

Table 1. Results of MOTIVATE 1 and 2 Trials of Maraviroc for Salvage HIV Therapy (Results in parenthesis are for MOTIVATE 2).

	Placebo	MVC QD	MVC BID
N	118 (91)	232 (182)	235 (191)
Median baseline CD4 count (cells/mm ³)	163 (174)	168 (174)	150 (182)
Mean baseline HIV-1 RNA log ₁₀ copies/ml	4.84 (4.89)	4.85 (4.84)	4.86 (4.87)
Proportion of patients with enfuvirtide in OBT	42% (45%)	43% (37%)	46% (39%)
Proportion of patients with < 2 active drugs predicted by resistance testing in OBT	66.1% (66.0%)	68.5% (62.6%)	75.7% (62.3%)
Mean change in HIV-1 RNA (log ₁₀ copies/ml)from baseline to 24 weeks	-1.03 (-0.93)	-1.82 (-1.95)	-1.95 (-1.97)
Mean change in CD4 count (cells/mm ³) from baseline to 24 weeks	+52 (+64)	+107 (+112)	+111 (+102)
Proportion of patients with HIV-1 RNA <400 copies/ml	31.4% (23.1%)	54.7% (55.5%)	60.4% (61.3)
Proportion of patients with HIV-1 RNA <50 copies/ml	24.6% (20.9%)	42.2% (45.6%)	48.5% (40.8%)